WO2008144508A3 - Modulating mhc class ii antigen presentation in dendritic cells prevents diabetes - Google Patents

Modulating mhc class ii antigen presentation in dendritic cells prevents diabetes Download PDF

Info

Publication number
WO2008144508A3
WO2008144508A3 PCT/US2008/063894 US2008063894W WO2008144508A3 WO 2008144508 A3 WO2008144508 A3 WO 2008144508A3 US 2008063894 W US2008063894 W US 2008063894W WO 2008144508 A3 WO2008144508 A3 WO 2008144508A3
Authority
WO
WIPO (PCT)
Prior art keywords
dendritic cells
mhc class
antigen presentation
cells prevents
prevents diabetes
Prior art date
Application number
PCT/US2008/063894
Other languages
French (fr)
Other versions
WO2008144508A2 (en
Inventor
Lisa Denzin
Original Assignee
Memorial Sloan-Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan-Kettering Cancer Center filed Critical Memorial Sloan-Kettering Cancer Center
Publication of WO2008144508A2 publication Critical patent/WO2008144508A2/en
Publication of WO2008144508A3 publication Critical patent/WO2008144508A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The instant invention provides method and compositions for the treatment of autoimmune disorders. The instant invention provides modulators of the DO/DM ratio or the activity of DO and/or DM.
PCT/US2008/063894 2007-05-17 2008-05-16 Modulating mhc class ii antigen presentation in dendritic cells prevents diabetes WO2008144508A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93075607P 2007-05-17 2007-05-17
US60/930,756 2007-05-17
US94014507P 2007-05-25 2007-05-25
US60/940,145 2007-05-25

Publications (2)

Publication Number Publication Date
WO2008144508A2 WO2008144508A2 (en) 2008-11-27
WO2008144508A3 true WO2008144508A3 (en) 2010-01-07

Family

ID=40122269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/063894 WO2008144508A2 (en) 2007-05-17 2008-05-16 Modulating mhc class ii antigen presentation in dendritic cells prevents diabetes

Country Status (1)

Country Link
WO (1) WO2008144508A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976551A (en) * 1991-11-15 1999-11-02 Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale Altered major histocompatibility complex (MHC) determinant and method of using the determinant
US20020004041A1 (en) * 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
US20040185043A1 (en) * 2001-05-09 2004-09-23 Ildstad Suzanne T. Hematopoietic stem cell chimerism to treat autoimmune disease
US6900016B1 (en) * 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976551A (en) * 1991-11-15 1999-11-02 Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale Altered major histocompatibility complex (MHC) determinant and method of using the determinant
US20020004041A1 (en) * 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
US6900016B1 (en) * 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof
US20040185043A1 (en) * 2001-05-09 2004-09-23 Ildstad Suzanne T. Hematopoietic stem cell chimerism to treat autoimmune disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DENZIN ET AL.: "Negative regulation by HLA-DO of MHC class II-restricted antigen processing.", SCIENCE, vol. 278, October 1997 (1997-10-01), pages 106 - 109, XP002918092, DOI: doi:10.1126/science.278.5335.106 *

Also Published As

Publication number Publication date
WO2008144508A2 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
WO2008103947A3 (en) Activation of human antigen-presenting cells through clec-6
MX2009008926A (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1.
WO2008103953A3 (en) Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1)
WO2006036994A3 (en) Modulators of crth2, cox-2 and faah
WO2009076676A3 (en) Compositions and methods for producing isoprene
WO2006137934A3 (en) Purposeful movement of human migratory cells away from an agent source
WO2010034015A3 (en) Modulating the alternative complement pathway
MX2009008430A (en) Anti-robo4 antibodies and uses therefor.
WO2009007852A3 (en) Multipotent/pluripotent cells and methods
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (en) Compounds and compositions as modulators of gpr119 activity.
WO2010021693A3 (en) Mif modulators
HK1097768A1 (en) Modified pyrimidine glucocorticoid receptor modulators
WO2010033771A3 (en) Modulators of hsp70/dnak function and methods of use thereof
WO2011072266A3 (en) Aminoacyl trna synthetases for modulating hematopoiesis
WO2007140472A3 (en) Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
EP3838298A3 (en) Psma binding ligand-linker conjugates and methods for using
EP2166991A4 (en) Pva-paa hydrogels
MX2010002028A (en) Methods and compositions for modulating t cells.
WO2009133378A3 (en) Products and methods for stimulating an immune response
WO2012091832A3 (en) Modulation of dynein in skin
WO2007121147A3 (en) Disheveled pdz modulators
TW200609559A (en) Contact lenses and methods for their design
WO2009134962A3 (en) Claudin-4 binding peptides, compositions and methods of use
WO2010057647A3 (en) Methods and compositions for the diagnosis and treatment of diabetes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08755696

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08755696

Country of ref document: EP

Kind code of ref document: A2